Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | QDPR | P09417 | 2/20 | 0.54 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3788041 | 0.98 | HTR2C (1.00) | HTR2CSIGMAR1QDPRSOS1HTR7 | |
| SCHEMBL14704909 | 0.90 | HTR2C (0.82) | HTR2CSIGMAR1QDPRSOS1HTR7 | |
| SCHEMBL14705031 | 0.85 | HTR2C (0.73) | HTR2CSIGMAR1HTR7HTR2AHTR3A | |
| SCHEMBL28688462 | 0.82 | SIGMAR1 (0.69) | HTR2CSIGMAR1QDPRHTR7MAPT | |
| SCHEMBL4791120 | 0.81 | SIGMAR1 (0.79) | HTR2CSIGMAR1QDPRHTR7HTR2A | |
| Hydrochloric Acid SCHEMBL28678896 | 0.80 | HTR2C (0.70) | HTR2CSIGMAR1QDPRHTR7MAPT | |
| SCHEMBL531984 | 0.80 | SIGMAR1 (1.00) | HTR2CSIGMAR1QDPRHTR7MAPT | |
| SCHEMBL21228136 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPR | |
| Hydrochloric Acid SCHEMBL4793458 | 0.79 | HTR2C (0.79) | HTR2CSIGMAR1QDPRHTR7MAPT | |
| SCHEMBL30431801 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPRHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| US-20090306144-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | VOLK BALAZS | 2009-12-10 | — | — | US | disclosed |
| US-20090281137-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | VOLK BALAZS | 2009-11-12 | — | — | US | disclosed |
| EP-1751138-B9 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-11-12 | — | — | EP | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| EP-1751138-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751134-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2005108390-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108388-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0271099-A2 | Substituted aminopropionic acid amides, process for their preparation, agents containing them and their use as well as the intermediates formed during the preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-06-15 | — | — | EP | disclosed |
| US-4575555-A | ANTIDEPRESSANTS | MEAD JOHNSON & COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
| US-4575555-A | ANTIDEPRESSANTS | MEAD JOHNSON & COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
| US-4487773-A | ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR2C 2910/4885SIGMAR1 234/4885QDPR 603/4885 |
| US-20090306144-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | HTR7, HTR2C, HTR1A | HTR2C 2/4885SIGMAR1 187/4885QDPR 207/4885 |
| US-20090281137-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | TPH2, TPH1, IDO1 | HTR2C 5/4885SIGMAR1 1428/4885QDPR 250/4885 |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, COASY | HTR2C 4552/4885SIGMAR1 628/4885QDPR 752/4885 |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | HTR2C 222/4885SIGMAR1 243/4885QDPR 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.